Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bullfrog AI Holdings, Inc. Common Stock (BFRG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: BFRG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -84.19% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.22M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.64 | 52 Weeks Range 1.23 - 4.84 | Updated Date 06/29/2025 |
52 Weeks Range 1.23 - 4.84 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -78.05% | Return on Equity (TTM) -141.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10607832 | Price to Sales(TTM) 262.62 |
Enterprise Value 10607832 | Price to Sales(TTM) 262.62 | ||
Enterprise Value to Revenue 205.12 | Enterprise Value to EBITDA -12.02 | Shares Outstanding 9415520 | Shares Floating 7018332 |
Shares Outstanding 9415520 | Shares Floating 7018332 | ||
Percent Insiders 25.96 | Percent Institutions 4.5 |
Upturn AI SWOT
Bullfrog AI Holdings, Inc. Common Stock
Company Overview
History and Background
Bullfrog AI Holdings, Inc. focuses on using artificial intelligence to advance drug development. Founded to leverage big data and machine learning to accelerate therapeutic breakthroughs, the company has aimed to transform how pharmaceuticals are discovered and developed.
Core Business Areas
- Artificial Intelligence Platform: Bullfrog AI's core offering is its bfLEAPu2122 analytics platform. This platform analyzes complex datasets to identify patterns and insights that can improve drug development success rates.
- Drug Development Partnerships: The company collaborates with pharmaceutical and biotechnology companies to apply its AI platform to their drug development programs.
- Proprietary Drug Development: Bullfrog AI also explores the use of its platform to develop its own portfolio of drug candidates.
Leadership and Structure
The company is led by a management team with experience in biotechnology, pharmaceuticals, and artificial intelligence. The organizational structure includes departments focused on AI development, drug development, and business development.
Top Products and Market Share
Key Offerings
- bfLEAPu2122 Analytics Platform: bfLEAPu2122 is Bullfrog AI's core product, an AI platform designed to analyze complex biomedical data. The company does not explicitly state its market share. The platform competes with other AI-driven drug discovery tools from companies like Exscientia (EXAI), Recursion Pharmaceuticals (RXRX), and Schru00f6dinger (SDGR).
Market Dynamics
Industry Overview
The pharmaceutical industry is increasingly adopting artificial intelligence to improve drug discovery and development. This includes identifying drug targets, predicting clinical trial outcomes, and personalizing medicine.
Positioning
Bullfrog AI is positioned as a provider of an AI-powered analytics platform for drug development. Its competitive advantage lies in its specific technology that can analyze complex datasets to find subtle signals that predict how a drug or treatment will behave.
Total Addressable Market (TAM)
The total addressable market for AI in drug discovery is estimated to be in the tens of billions of dollars. Bullfrog AI is positioned to capture a share of this market through partnerships and internal drug development programs.
Upturn SWOT Analysis
Strengths
- Proprietary AI Platform
- Expertise in analyzing complex biomedical data
- Potential for improving drug development success rates
Weaknesses
- Relatively small size compared to established pharmaceutical and technology companies
- Dependence on partnerships for revenue
- Limited publicly available information on customer acquisition and sales performance
Opportunities
- Growing adoption of AI in drug development
- Potential for expanding partnerships with pharmaceutical companies
- Opportunity to develop proprietary drug candidates using its platform
Threats
- Competition from larger and more established AI and pharmaceutical companies
- Risk of technological obsolescence
- Challenges in demonstrating the value of its platform to potential customers
Competitors and Market Share
Key Competitors
- EXAI
- RXRX
- SDGR
- ADCT
Competitive Landscape
Bullfrog AI faces competition from larger companies with established positions in the pharmaceutical and AI sectors. Its advantage lies in specialized technology, but its disadvantages are a smaller scale and limited financial resources.
Growth Trajectory and Initiatives
Historical Growth: Due to the lack of available financial data, it's challenging to determine historical growth trends.
Future Projections: Future growth is dependent on securing partnerships and successfully deploying its AI platform. Analyst projections are limited due to data scarcity.
Recent Initiatives: Bullfrog AI has focused on securing partnerships with companies in the pharmaceutical and biotechnology industries to apply its AI platform.
Summary
Bullfrog AI is a company focused on AI-driven drug discovery. It has a unique analytics platform that has the potential to improve drug development. Lack of publicly available data makes it difficult to assess its progress. The company should focus on its AI platform and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Analysis Reports
Disclaimers:
The information provided is based on publicly available data and is for informational purposes only. It does not constitute financial advice. Market share data is estimated due to limited information provided by company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bullfrog AI Holdings, Inc. Common Stock
Exchange NASDAQ | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2023-02-13 | Founder, Chairman & CEO Mr. Vininder Singh | ||
Sector Healthcare | Industry Health Information Services | Full time employees - | Website https://www.bullfrogai.com |
Full time employees - | Website https://www.bullfrogai.com | ||
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases; and Modified HSV-1, which is in the discovery phase, for the treatment of modified colorectal cancer. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It also has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.